A Study to Confirm the Accuracy of Locally Advanced Gastric Cancer Diagnosis

Summary

With the introducing of neoadjuvant therapy, it becomes ever more important to evaluate the preoperative TNM (cTNM) stage accurately facilitating preoperative treatment as well as the adjuvant therapy.

At present, the recommendation of neoadjuvant chemotherapy varies among guidelines especially between eastern and western countries. According to the updated Japanese gastric cancer treatment guidelines (ver.5), neoadjuvant chemotherapy is the recommended standard procedure for patients with cT2-4 stages. However, the acknowledgement of preoperative therapy accompanied by the higher risk of overtreatment. As mentioned in JCOG1302-A, the overall precision rate in cT staging is 38.8%. Patients diagnosed with pI stages postoperatively account for 6.5% in cT3-4N+ treatment indicating more likely to avoiding the overtreatment comparing to patients with other cT stages.

Inspired by JCOG1302-A, this multicentre study prospectively collect data in preoperative TNM staging assessment using CT(computed tomography, CT) scan and the postoperative TNM (pTNM) staging according to histopathologically examination. By analyzing the accordance between the cTNM and pTNM, this study aims to evaluate the current accuracy of the cTNM staging in china, verifying the proportion of pI stages less than 5% in cIII stage diagnosis patients, learning the overtreating rate in neoadjuvant chemotherapy in China and furthermore, to discover the scope of beneficiaries for neoadjuvant chemotherapy.

Conditions

• Gastric Cancer
• Gastric Cancer Stage
• CT
• Neoadjuvant Therapy

Interventions

PROCEDURE

Preoperative staging--D2 gastrectomy--Postoperative staging

Preoperative TNM staging under CT scan plus endoscopy endoscopic biopsy, and postoperative staging after D2 gastrectomy

Sponsors & Collaborators

• RenJi Hospital

  collaborator OTHER

• Ruijin Hospital

  collaborator OTHER

• West China Hospital

  collaborator OTHER

• Beijing 302 Hospital

  collaborator OTHER

• Fudan University

  collaborator OTHER

• Peking University International Hospital

  collaborator OTHER

• Guangdong Provincial Hospital of Traditional Chinese Medicine

  collaborator OTHER

• Fujian Medical University Union Hospital

  collaborator OTHER

• First Affiliated Hospital Xi'an Jiaotong University

  collaborator OTHER

• Chinese PLA General Hospital

  collaborator OTHER

• First Affiliated Hospital of Xinjiang Medical University

  collaborator OTHER

• Tianjin Medical University General Hospital

  collaborator OTHER

• The Second Affiliated Hospital of Dalian Medical University

  collaborator OTHER

• Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

  collaborator OTHER

• Peking University People's Hospital

  collaborator OTHER

• Weifang People's Hospital

  collaborator OTHER

• Second Hospital of Jilin University

  collaborator OTHER

• Fujian Province Tumor Hospital

  collaborator OTHER

• Shanxi Province Cancer Hospital

  collaborator OTHER

• The First Affiliated Hospital of Nanchang University

  collaborator OTHER

• Tianjin Medical University Cancer Institute and Hospital

  collaborator OTHER

• Shanghai Zhongshan Hospital

  collaborator OTHER

• First Affiliated Hospital, Sun Yat-Sen University

  collaborator OTHER

• The Affiliated Hospital of Qingdao University

  collaborator OTHER

• The First Affiliated Hospital of Xiamen University

  collaborator OTHER

• Beijing Hospital

  collaborator OTHER_GOV

• Beijing Friendship Hospital

  collaborator OTHER

• Qingdao Municipal Hospital

  collaborator OTHER

• Guangdong Provincial People's Hospital

  collaborator OTHER

• Affiliated Hospital of Qinghai University

  collaborator OTHER

• Shandong Provincial Hospital

  collaborator OTHER_GOV

• The First Hospital of Jilin University

  collaborator OTHER

• Nanfang Hospital, Southern Medical University

  collaborator OTHER

• Zhongshan Hospital Xiamen University

  collaborator OTHER

• Hebei Medical University Fourth Hospital

  collaborator OTHER

• Peking University

  lead OTHER

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2020-07-01

Primary Completion

2022-04-30

Completion

2022-10-31

Countries

• China

Study Locations